CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy
- Author(s)
- Baumgartner, F; Dickinson, MJ; Blombery, P;
- Journal Title
- Blood
- Publication Type
- Online publication before print
- Abstract
- Engineered T-cells have transformed hematooncology, but CAR transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR-T therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR-T manufacture, vector integration, construct biology and post-infusion selection may contribute to different degrees. We review reported cases of CAR-transgenic T-cell lymphoproliferative neoplasms (CTTLN) and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1182/blood.2026033477
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2026033477- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-10-12 05:40:41
Last Modified: 2026-10-12 05:41:16